Pulmonary fibrosis Respiratory
Conditions
Interventions
This is an observational study, consisting of three study visits:
Visit 1: Baseline assessments and cardiopulmonary exercise test to determine gas exchange threshold (GET) and exercise capacity (VO2
therefore, patients may perform 'moderate' first or 'heavy' first. The second bout will therefore be the condition that they have not already done.
Sponsors
University of Exeter
Eligibility
Sex/Gender
All
Age
35 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis of PF 2. Aged 35 to 85 years 3. Able to provide informed consent/assent 4. Able to perform CPET
Exclusion criteria
Exclusion criteria: 1. Presence of severe co-morbidity limiting mobilisation or physical activity participation (e.g. Orthopaedic, cardiac or neurological condition) 2. Previous lung transplantation 3. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak volume of oxygen consumption (VO2peak) measured using CPET (mL.kg-1.min-1 and L.min-1) at all 3 study visits;Peak work rate (WRpeak) measured using CPET (W) at all 3 study visits;Volume of oxygen consumption at Gas Exchange Threshold (GET) measured using CPET (mL.kg-1.min-1 and L.min-1) at all 3 study visits;Peak minute ventilation (VEpeak) measured using CPET (L/min) at all 3 study visits;Heart Rate measured using CPET (beats·min-1) at all 3 study visits | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional disability due to dyspnoea measured using the Modified Medical Research Council (mMRC) Breathlessness scale (0-10) at all 3 study visits;Self-perceived exertion measured using the Rate of Perceived Exertion (RPE) scale (0-10) at all 3 study visits;Affective response to exercise measured using the Affective Response to Exercise scale (-5 to +5) at all 3 study visits;Oxygen saturations measured using a pulse oximeter (%sp02) at all 3 study visits;Lung function measured using a spirometer or body plethysmograph to assess diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) at Visit 1;Lung sounds measured using a digital stethoscope at Visit 1;Volatile Organic Compounds (VOCs) measured using Spironose at Visit 1;Grip strength measured using a grip strength dynamometer (N) at Visit 1;Acceptability measured using the Theoretical Framework of Acceptability (TFA) via a questionnaire (customised) at Visit 1, 2 and 3;Health status measured using the King's Brief Interstitial Lung Disease (K-BILD) questionnaire at Visit 1;Symptoms and quality of life measured using the Living with Pulmonary Fibrosis (L-PF) questionnaire at Visit 1;Lung resistance and reactance measured using oscillometry; R5 (resistance at 5 Hz), X5 (reactance at 5 Hz), R20 (resistance at 20 Hz), and the difference between R5 and R20 (R5-R20) at Visit 1 | — |
Countries
England, United Kingdom
Contacts
Public ContactOwen Tomlinson
Outcome results
None listed